NeuroOne to Participate at the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26th, 2021
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced its participation in the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced its participation in the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26, 2021. The summit includes an on-demand presentation for registered participants and one-on-one meetings. NeuroOne focuses on minimally invasive solutions for neurological disorders, including epilepsy and Parkinson's disease. The company has received FDA clearance for its Evo cortical technology, developed in partnership with Mayo Clinic and WARF, and is committed to enhancing surgical care options.
Details
News Market Reaction – NMTC
The recorded move for NMTC in the trading session of this news was -4.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., May 19, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that management will participate in the upcoming investor conference:
Oppenheimer Medtech, Tools and Diagnostics Summit
- May 26, 2021 (On demand presentation for registered participants and available for 1x1 meetings)
https://www.oppenheimer.com/events/2021/medtech-day-conference.aspx
To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne's Evo™ (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.
View original content to download multimedia:http://www.prnewswire.com/news-releases/neuroone-to-participate-at-the-oppenheimer-medtech-tools-and-diagnostics-summit-on-may-26th-2021-301294364.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.